Cart
sales@molnova.com
Ralmitaront
CAS No. 2133417-13-5
Ralmitaront( RO6889450 )
Catalog No. M23969 CAS No. 2133417-13-5
Ralmitaront is a potent, orally active partial agonist of the trace amine-associated receptor 1 (TAAR1).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 267 | In Stock |
|
| 10MG | 434 | In Stock |
|
| 25MG | 669 | In Stock |
|
| 50MG | 896 | In Stock |
|
| 100MG | 1269 | In Stock |
|
| 200MG | 1701 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRalmitaront
-
NoteResearch use only, not for human use.
-
Brief DescriptionRalmitaront is a potent, orally active partial agonist of the trace amine-associated receptor 1 (TAAR1).
-
DescriptionRalmitaront is a potent, orally active partial agonist of the trace amine-associated receptor 1 (TAAR1).
-
In Vitro——
-
In Vivo——
-
SynonymsRO6889450
-
PathwayOthers
-
TargetOther Targets
-
Recptoramine-associated receptor 1 (TAAR1)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2133417-13-5
-
Formula Weight314.38
-
Molecular FormulaC17H22N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:90mg/ml(286.28mM; Need ultrasonic)
-
SMILESCCc1c(C)c(C(Nc2ccc([C@@H]3OCCNC3)cc2)=O)n[nH]1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Brady LS, Potter WZ, Gordon JA. Redirecting the revolution: new developments in drug development for psychiatry. Expert Opin Drug Discovery. 2019;14:1213–1219.
molnova catalog
related products
-
Guanidinosuccinic ac...
Guanidinosuccinic acid (GSA) has been identified as a uremic toxin?is a nitrogenous metabolite isolated in excess from serum and urine.
-
alpha-Costic acid
α-Costic acid, a plant sesquiterpene with acaricidal activity against Varroa destructor.
-
Etifoxine hydrochlor...
Etifoxine is an anxiolytic and anticonvulsant drug.?Unlike benzodiazepines, etifoxine appears to produce its anxiolytic effects by binding to β2 and β3 subunits of the GABAA receptor complex, and so is acting at a different target site to benzodiazepines, although the physiological effect that is produced is similar to that of benzodiazepines.
